舍曲林妊娠期药代动力学特征可预测产后抑郁症状
本研究为前瞻性纵向观察研究,纳入185名重性抑郁障碍孕妇(205次妊娠),在妊娠期及产后第一年随访,分析舍曲林及其代谢物浓度与产后抑郁症状的关系。结果发现舍曲林药代动力学存在不同轨迹,产后舍曲林暴露与较低EPDS评分相关,而N-去甲基舍曲林暴露与所有抑郁量表评分较高相关,提示治疗药物监测可能有助于识别产后抑郁风险患者。
要点
- 妊娠期舍曲林24小时浓度剂量比变异大,呈现不同药代动力学轨迹。
- 产后舍曲林暴露与较低EPDS评分相关(P<.05)。
- 产后N-去甲基舍曲林暴露与所有抑郁量表评分较高相关(P<.001)。
核心结论
- 舍曲林药代动力学特征在孕妇中表现各异,且与产后抑郁症状相关。
- 治疗药物监测可能为识别有产后抑郁症状潜在风险的患者提供临床线索。
研究设计与样本
- 前瞻性观察性纵向研究,纳入185名重性抑郁障碍孕妇(共205次妊娠)。
- 孕妇在妊娠<16周入组,妊娠期每4-8周随访一次,产后第一年继续随访。
- 基线进行结构化临床访谈和人口学信息采集,随访时测量药物及代谢物浓度和心理学量表。
主要发现
- 舍曲林平均24小时浓度剂量比在妊娠期和产后变异大,舍曲林有3种轨迹,N-去甲基舍曲林有5种轨迹。
- 产后舍曲林药物暴露与较高EPDS评分呈负相关(P<.05)。
- 产后N-去甲基舍曲林暴露与所有测量抑郁量表评分较高相关(P<.001)。
- 产后较高的母体/代谢物比值与较高CGI评分相关(P<.05)。
关键数值与推荐
- 舍曲林暴露以标准化24小时浓度剂量比(C/D)表示,母体/代谢物比值(P/M)亦被计算。
- 抑郁评估工具包括汉密尔顿抑郁量表17项、贝克抑郁量表、爱丁堡产后抑郁量表(EPDS)和临床总体印象量表(CGI)。
临床怎么用
- 临床可考虑对妊娠期使用舍曲林的孕妇进行治疗药物监测,以了解其药代动力学变化。
- 产后舍曲林及代谢物浓度可能有助于识别产后抑郁症状风险较高的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To characterize pharmacokinetic changes of sertraline and its metabolite during pregnancy and postpartum, and their relationship to maternal postpartum depressive symptoms. METHODS: This was a prospective observational, longitudinal study of pregnant women with a major depressive disorder treated with sertraline (N = 185 women, 205 pregnancies). Women were enrolled at <16 weeks' gestation and followed at 4-8 week intervals throughout pregnancy and the first postpartum year. Baseline measures included structured clinical interviews and demographic information. Drug and metabolite concentrations and psychometric measures (study outcomes) (ie, Hamilton Rating Scale for depression - 17 item, Beck Depression Inventory, Edinburgh Postnatal Depression Scale [EPDS], Clinical Global Impression [CGI]) were measured at follow-up visits. Serum sertraline and N-desmethylsertraline exposure were reported asstandardized 24-h concentration-to-dose (C/D) and parent to metabolite (P/M) ratios. Linear mixed-effects and latent trajectory models were used to characterize longitudinal patterns in concentration measures across pregnancy and postpartum, and their association with study outcomes. RESULTS: Mean 24-h C/D ratios showed high variability throughout pregnancy and postpartum that were characterized by three trajectories for sertraline and five for N-desmethylsertraline and P/M ratio corresponding to different sertraline pharmacokinetic profiles. At postpartum, sertraline drug exposure was inversely associated with higher EPDS score (P < .05), while N-desmethylsertraline exposure was associated with higher scores for all measured depression scales (P < .001). Higher P/M ratios had higher CGI scores (P < .05) postpartum. CONCLUSION: Sertraline pharmacokinetic profiles varied across pregnant women and were associated with postpartum depressive symptoms. The use of therapeutic monitoring may provide clinical insight that can be useful for identifying patients with a potential toward depressive symptoms.
引用
- Illamola SM, Stowe ZN, Kalin ML, et al. Pharmacokinetic profiles of sertraline in pregnancy as a predictor of postpartum depressive symptoms. Br J Clin Pharmacol. 2025. PMID: 41058051. doi:10.1002/bcp.70283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。